CVRx (CVRX) to Release Quarterly Earnings on Tuesday

CVRx (NASDAQ:CVRX) will likely be issuing its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect the company to announce earnings of ($0.50) per share and revenue of $14.1560 million for the quarter. CVRx has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS.Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

CVRx (NASDAQ:CVRX) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.05). The company had revenue of $13.59 million during the quarter, compared to analyst estimates of $13.22 million. CVRx had a negative net margin of 95.61% and a negative return on equity of 79.31%. On average, analysts expect CVRx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CVRx Price Performance

Shares of CVRX opened at $10.19 on Friday. The company’s 50-day moving average is $8.51 and its 200-day moving average is $7.43. The company has a debt-to-equity ratio of 0.85, a current ratio of 11.99 and a quick ratio of 10.78. The firm has a market capitalization of $266.49 million, a PE ratio of -4.85 and a beta of 1.26. CVRx has a fifty-two week low of $4.30 and a fifty-two week high of $18.55.

Analyst Ratings Changes

Several research analysts have weighed in on CVRX shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $11.00 price target on shares of CVRx in a report on Tuesday, August 5th. Weiss Ratings restated a “sell (e+)” rating on shares of CVRx in a research note on Thursday. Finally, William Blair upgraded CVRx to a “strong-buy” rating in a research report on Monday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $14.00.

Hedge Funds Weigh In On CVRx

Several hedge funds and other institutional investors have recently modified their holdings of the business. Balyasny Asset Management L.P. raised its holdings in shares of CVRx by 65.5% during the 2nd quarter. Balyasny Asset Management L.P. now owns 674,685 shares of the company’s stock worth $3,967,000 after buying an additional 267,063 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of CVRx by 7.6% in the 2nd quarter. Bank of America Corp DE now owns 89,049 shares of the company’s stock valued at $524,000 after purchasing an additional 6,312 shares in the last quarter. Cresset Asset Management LLC grew its holdings in shares of CVRx by 3.5% during the 2nd quarter. Cresset Asset Management LLC now owns 53,542 shares of the company’s stock valued at $315,000 after purchasing an additional 1,823 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of CVRx by 238.1% during the 2nd quarter. Marshall Wace LLP now owns 350,080 shares of the company’s stock valued at $2,058,000 after purchasing an additional 246,548 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in CVRx during the 2nd quarter worth approximately $155,000. Institutional investors own 75.27% of the company’s stock.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.